Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease
Intestinal Research
;
: 609-618, 2018.
Article
in English
| WPRIM
| ID: wpr-717943
ABSTRACT
BACKGROUND/AIMS:
The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate the safety of H. pylori eradication therapy for IBD patients.METHODS:
IBD patients with H. pylori eradication from 2005 to 2015 (eradication group) and control patients (non-eradication group; 2 paired IBD patients without H. pylori eradication matched with each eradicated patient) were included. IBD exacerbation (increased/additional IBD drug or IBD-associated hospitalization/surgery) and disease improvement based on the physicians’ global assessment were investigated at baseline, and at 2 and 6 months after eradication or observation.RESULTS:
A total of 429 IBD (378 ulcerative colitis, 51 Crohn’s disease) patients, comprising 144 patients in the eradication group and 285 patients in the non-eradication group, were enrolled at 25 institutions. IBD exacerbation was comparable between groups (eradication group 8.3% at 2 months [odds ratio, 1.76; 95% confidence interval, 0.78–3.92; P=0.170], 11.8% at 6 months [odds ratio, 1.60; 95% confidence interval, 0.81–3.11; P=0.172]). Based on the physicians’ global assessment at 2 months, none of the patients in the eradication group improved, whereas 3.2% of the patients in the non-eradication group improved (P=0.019). Multivariate analysis revealed that active disease at baseline, but not H. pylori eradication, was an independent factor for IBD exacerbation during 2 months’ observation period. The overall eradication rate was 84.0%–comparable to previous reports in non-IBD patients.CONCLUSIONS:
H. pylori eradication therapy does not alter the short-term disease activity of IBD.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Inflammatory Bowel Diseases
/
Colitis, Ulcerative
/
Multivariate Analysis
/
Retrospective Studies
/
Cohort Studies
/
Helicobacter pylori
/
Helicobacter
/
Clarithromycin
/
Metronidazole
Type of study:
Etiology study
/
Incidence study
/
Observational study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Intestinal Research
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS